Exploring the Potential of GLP-1 Drugs in Dementia Prevention
The potential advantages of GLP-1 drugs keep expanding. A recent review of primarily preclinical studies has connected these widely-used diabetes and weight-loss medications to a reduction in some molecular signs of dementia.
Researchers at Anglia Ruskin University in the UK conducted a review of 30 published studies focusing on cell cultures and lab animals.
They specifically examined how four different GLP-1 medications affect the damaging accumulation of amyloid-beta and tau proteins in the brain, which are associated with Alzheimer’s disease.
Out of the studies reviewed, 22 indicated a decrease in amyloid-beta plaques, while 19 showed a reduction in tau tangles. These abnormal protein clusters are believed to harm and kill neurons in the context of Alzheimer’s, despite other potential factors being considered as well.
It’s essential to note that we’re still quite far from establishing that GLP-1 drugs like Ozempic and Wegovy can actually lower dementia risk, especially since the review identified only two small human trials.
However, the accumulating evidence from cell and animal studies does hint at a possible connection.
“This new review offers one of the most comprehensive analyses on how GLP-1 drugs might interact with the mechanisms behind Alzheimer’s,” comments physiologist Simon Cork.
He adds, “Our findings highlight various biological pathways through which GLP-1 drugs may impact Alzheimer’s, including reducing inflammation and enhancing insulin signaling in the brain.”
These GLP-1 medications mimic the glucagon-like peptide-1 hormone, functioning as receptor agonists. They slow digestion, encourage insulin release, and help limit appetite.
Commonly recognized by brand names such as Wegovy, Ozempic, and Mounjaro, these drugs contain active ingredients like semaglutide, liraglutide, exenatide, and dulaglutide. Liraglutide appeared most frequently in the review and was the most reliable in lowering both amyloid-beta and tau to safer levels.
Exenatide, while showing the least impact overall, still demonstrated some association with reduced amyloid-beta and tau in select studies.
Two small clinical trials were also reviewed, yielding mixed results. One trial managed to preserve brain cell metabolism, while another reported reduced amyloid-beta in extracellular vesicles. Yet neither trial showed that GLP-1 drugs effectively limited amyloid-beta accumulation in the brain or helped prevent cognitive decline.
“While human studies confirming an effect on cognitive decline are still lacking, current evidence suggests that these drugs might have a preventive role rather than benefiting those with established cognitive loss,” Cork notes.
Previous research indicates that individuals using GLP-1 medications may be less likely to develop dementia in certain cases. On the flip side, other studies involving early Alzheimer’s or mild cognitive impairment have yielded disappointing results. For instance, one recent study found no link between semaglutide and a slowdown in cognitive decline.
It’s also important to remember that both obesity and diabetes — the conditions GLP-1 drugs aim to treat — are connected to dementia risk. Unpacking the various mechanisms at play and their effects on dementia will likely take time.
There’s still much to uncover about how GLP-1 medicines could combat toxic protein buildup and dementia. Researchers suggest that reductions in inflammation and protein production, along with improved insulin signaling, might play a role.
“With over three-quarters of preclinical studies showing reductions in amyloid-beta or tau, and initial human studies providing promising signs, GLP-1 drugs remain strong candidates for future Alzheimer’s prevention research,” Cork states.
“More extensive early-stage clinical trials are necessary to ascertain whether these encouraging signals actually translate into real benefits for patients.”
The findings have been published in Molecular and Cellular Neuroscience.
